LONDON (Alliance News) - hVIVO PLC Monday said that an initial revenue of results from its PrEP-001 phase IIa flu study suggests a favourable outcome.
The study is of PrEP-001, a treatment for the prevention of upper respiratory tract viral infections, which is the lead programme of PrEP Biopharm Ltd, which hVIVO bought a stake in last November.
The study's primary objective is assessing the changes in symptoms in healthy subjects receiving PrEP-001 compared to those receiving a placebo. An initial review showed a decrease in the number of symptoms in subjects in the active treatment group compared to the placebo.
"We are delighted to report such encouraging initial results for the first of our PrEP-001 Phase IIa studies. While subject to more detailed statistical review and analysis, these results speak to the potential we saw in the PrEP-001 study using hVIVO's platform in 2013-14. I look forward to updating our investors further once these results are finalised," said Chief Executive Officer of hVIVO Kym Denny in a statement.
Shares in hVIVO were down 1.0% at 201.00 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
hVIVO (HVO)